Terms: = Liver cancer AND GPC3, OCI-5, 2719, ENSG00000147257, SGBS, SGB, DGSX, SDYS, P51654, AC002420_1, SGBS1 AND Treatment
132 results:
1. Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors.
Yang LM; Wang HJ; Li SL; Gan GH; Deng WW; Chang YS; Zhang LF
World J Gastroenterol; 2024 Mar; 30(11):1533-1544. PubMed ID: 38617449
[TBL] [Abstract] [Full Text] [Related]
2. Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma.
Lin F; Clift R; Ehara T; Yanagida H; Horton S; Noncovich A; Guest M; Kim D; Salvador K; Richardson S; Miller T; Han G; Bhat A; Song K; Li G
J Nucl Med; 2024 Apr; 65(4):586-592. PubMed ID: 38423788
[TBL] [Abstract] [Full Text] [Related]
3. Aptamer-bivalent-cholesterol-mediated proximity entropy-driven exosomal protein reporter for tumor diagnosis.
Fan Z; Zhou J; Shu Q; Dong Y; Li Y; Zhang T; Bai G; Yu H; Lu F; Li J; Zhao X
Biosens Bioelectron; 2024 May; 251():116104. PubMed ID: 38368644
[TBL] [Abstract] [Full Text] [Related]
4. GenX caused liver injury and potential hepatocellular carcinoma of mice via drinking water even at environmental concentration.
Wan G; Zhang Z; Chen J; Li M; Li J
Environ Pollut; 2024 Apr; 346():123574. PubMed ID: 38365076
[TBL] [Abstract] [Full Text] [Related]
5. Smart glypican-3-targeting peptide-chlorin e6 conjugates for targeted photodynamic therapy of hepatocellular carcinoma.
Fang Y; Ma H; Zhang X; Zhang P; Li Y; He S; Sheng C; Dong G
Eur J Med Chem; 2024 Jan; 264():116047. PubMed ID: 38118394
[TBL] [Abstract] [Full Text] [Related]
6. WGCNA combined with machine learning to find potential biomarkers of liver cancer.
Lv JH; Hou AJ; Zhang SH; Dong JJ; Kuang HX; Yang L; Jiang H
Medicine (Baltimore); 2023 Dec; 102(50):e36536. PubMed ID: 38115320
[TBL] [Abstract] [Full Text] [Related]
7. The role and mechanism of HIF-1α-mediated glypican-3 secretion in hypoxia-induced tumor progression in hepatocellular carcinoma.
Wang P; Tong K; Li Y; Li X; Zhang Y; Gu J; Lei P; Yan S; Hu P
Cell Signal; 2024 Feb; 114():111007. PubMed ID: 38081444
[TBL] [Abstract] [Full Text] [Related]
8. Glutamine synthetase and hepatocellular carcinoma.
Jiang J; Hu Y; Fang D; Luo J
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102248. PubMed ID: 37979911
[TBL] [Abstract] [Full Text] [Related]
9. gpc3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
Lu LL; Xiao SX; Lin ZY; Bai JJ; Li W; Song ZQ; Zhou YH; Lu B; Wu WZ
Cell Biol Toxicol; 2023 Dec; 39(6):3101-3119. PubMed ID: 37853185
[TBL] [Abstract] [Full Text] [Related]
10. The Role of microRNAs in Regulating cancer Cell Response to Oxaliplatin-Containing Regimens.
Tavakoli Pirzaman A; Ebrahimzadeh Pirshahid M; Babajani B; Rahmati A; Niknezhad S; Hosseinzadeh R; Taheri M; Ebrahimi-Zadeh F; Doostmohamadian S; Kazemi S
Technol Cancer Res Treat; 2023; 22():15330338231206003. PubMed ID: 37849311
[TBL] [Abstract] [Full Text] [Related]
11. Identification and validation of microtubule depolymerizing agent, CYT997, as a potential drug candidate for hepatocellular carcinoma.
Ahmad F; Ma L; Wei W; Liu Y; Hakim I; Daugherty A; Mujahid S; Radin AA; Chua MS; So S
Liver Int; 2023 Dec; 43(12):2794-2807. PubMed ID: 37833852
[TBL] [Abstract] [Full Text] [Related]
12. A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma.
Liu Q; Song Q; Luo C; Wei J; Xu Y; Zhao L; Wang Y
Mol Immunol; 2023 Oct; 162():125-132. PubMed ID: 37677989
[TBL] [Abstract] [Full Text] [Related]
13. Predicting glypican-3 expression in hepatocellular carcinoma: A comprehensive analysis using combined contrast-enhanced ultrasound and clinical factors.
Li N; Dong T; Wang P; Li Q; Nie F
Clin Hemorheol Microcirc; 2023; 85(4):407-420. PubMed ID: 37638421
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathological features and differential diagnosis of gastric metastases.
Chen W; Liu C; Liu Y; Yuan J; Wang Z
World J Surg Oncol; 2023 Aug; 21(1):258. PubMed ID: 37608278
[TBL] [Abstract] [Full Text] [Related]
15. Glypican-3 (GPC-3) Structural Analysis and Cargo in Serum Small Extracellular Vesicles of Hepatocellular Carcinoma Patients.
Mauro M; Ugo P; Walton Z; Ali S; Rastellini C; Cicalese L
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446098
[TBL] [Abstract] [Full Text] [Related]
16. Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells.
He C; Jaffar Ali D; Qi Y; Li Y; Sun B; Liu R; Sun B; Xiao Z
J Nanobiotechnology; 2023 May; 21(1):154. PubMed ID: 37202772
[TBL] [Abstract] [Full Text] [Related]
17. The efficacy and adverse effects of nivolumab and lenvatinib in the treatment of advanced hepatocellular carcinoma.
Wen S; Zeng J; Zhong L; Ye J; Lai X
Cell Mol Biol (Noisy-le-grand); 2022 Nov; 68(11):53-57. PubMed ID: 37114307
[TBL] [Abstract] [Full Text] [Related]
18. Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.
Cheng F; Hansson VC; Georgolopoulos G; Mani K
Oncotarget; 2023 Mar; 14():219-235. PubMed ID: 36944188
[TBL] [Abstract] [Full Text] [Related]
19. H-rGO-Pd NPs Nanozyme Enhanced Silver Deposition Strategy for Electrochemical Detection of Glypican-3.
Li G; Wang B; Li L; Li X; Yan R; Liang J; Zhou X; Li L; Zhou Z
Molecules; 2023 Feb; 28(5):. PubMed ID: 36903516
[TBL] [Abstract] [Full Text] [Related]
20. Bispecific gpc3/PD‑1 CAR‑T cells for the treatment of HCC.
Li D; Qin J; Zhou T; Li Y; Cheng X; Chen Z; Chen J; Zheng WV
Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36896779
[TBL] [Abstract] [Full Text] [Related]
[Next]
